Utilization and spending on lipid lowering therapies in medicaid from 2018 to 2022
Authors' conclusion
Between 2018 and 2022, annual prescription fills for lipid lowering therapies in Medicaid remained stable while spending on these medications increased, driven by increased utilization of PCSK9 inhibitors, icosapent ethyl, and bempedoic acid.
Study context
- Population
- Medicaid prescription fills for 32 lipid lowering drug formulations (18 brand-name, 14 generic), Medicaid Spending by Drug Dataset
- Participants
- 115 million prescription fills
- Exposure
- Utilization and spending on lipid lowering therapies in Medicaid, 2018 vs 2022
- Outcome
- Change in utilization (annual prescription fills) and spending on lipid lowering medications
- Follow-up
- 2018 to 2022
Main finding
As reported in the abstract
| Group | Annual fills | Annual spending |
|---|---|---|
| 2018 | 22.7 million per year | $348.3 million |
| 2022 | 22.9 million per year | $394.4 million per year |
Annual fills
201822.7 million per year
202222.9 million per year
Annual spending
2018$348.3 million
2022$394.4 million per year
- Increase in annual prescription fills
- 1.2%
- Increase in annual Medicaid spending
- 13.2%
Observational data: associations, not effects.
Further findings
| Outcome | 2018 | 2022 |
|---|---|---|
| Statins: annual fills and spending | ||
| Fills | 20.4 million | 20.3 million |
| Spending | $243.9 million | $228.3 million |
| PCSK9 inhibitors: annual fills and spending | ||
| Fills | 7,617 | 121,737 |
| Spending | $8.9 million | $65.7 million |
| Icosapent ethyl: annual fills and spending | ||
| Fills | 32,527 | 180,291 |
| Spending | $10.2 million | $50.2 million |
| Bempedoic acid: annual fills and spending | ||
| Fills | 494 | 4,619 |
| Spending | $215,499 | $2.2 million |
Statins: annual fills and spending
- Statin utilization stable; spending decreased
Original publication
Utilization and spending on lipid lowering therapies in medicaid from 2018 to 2022. Am Heart J. Published 25 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →